Please assess the completion status of the following clinical trial:

Trial Title: Esketamine Combined With Pregabalin on Acute Postoperative Pain in Patients Undergoing Resection of Spinal Neoplasms.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient undergoing elective spinal cord neoplasms resection;~* Ages between 18 and 65 years old;~* American Society of Anaesthesiology (ASA) status I-III;~* Signed informed consent.~Exclusion Criteria:~* Previous adverse reaction to ketamine, s-ketamine or pregabalin;~* Patients with a diagnosed history of severe chronic pain;~* Patients with long-term analgesic treatment(gabapentin/opioids/ketamine);~* Patients with aphasia or inability to cooperate with the pain assessments;~* Known sever insufficiency of vitals(such as heart failure/renal dysfunction/hepatic failure);~* Patients with a diagnosed history of psychiatric disorder;~* Patients treated with gabapentin/pregabalin in the last three months;~* Drug abuse;~* Body mass index (BMI) \> 35 kg/m2 ;~* Pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- S-ketamine and pregabalin (Type: EXPERIMENTAL): None
- Normal saline and placebo capsule (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).